CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...

A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in ...

Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Maddocks: So let ...

(RTTNews) - Incyte (INCY) and MorphoSys AG (MOR) said that the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo ...

Lower socioeconomic status is associated with poor survival in lymphoma. Patients with follicular lymphoma (FL) lived longer if they had private insurance, according to a study that examined patient ...

"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...

Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset This multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using ...

Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision ...